Murín J, Borovský M, Payer J, Killinger Z, Stecová L
I. interná klinika FN, Bratislava.
Vnitr Lek. 1995 Oct;41(10):672-6.
The authors pay attention to changes of the serum lipid spectrum and blood sugar level during hormonal substitution treatment of menopausal women. The observation pertains to 70 women (mean age 50 years, 36 women after hysterectomy, mean duration of the menopause 4.5-5.0 years). The lipid spectrum and blood sugar level were assessed by enzyme methods from venous blood collected in the morning on fasting before administration of treatment (a combination of oestrogen and gestagen), on average after 8 months on these drugs. With regard to total cholesterol and HDL-cholesterol before treatment the women were, consistent with recommendations of the European Society for Atherosclerosis divided into four groups: hypercholesterolaemic group (5.2-7.8 mmol/l) 47 women; hypercholesterolaemic group with a reduced HDL-cholesterol (less than 1.1 mmol/l) 5 women; a very high cholesterol group (more than 7.8 mmol/l) one woman only; and women with a normal lipid profile (total cholesterol less than 5.2 mmol/l), 17 women. The authors recorded in the whole group a significant drop of total cholesterol (-0.30 mmol/l), VLDL-cholesterol (-0.08 mmol/l) and triacylglycerols (-0.27 mmol/l) and a significant rise of HDL-cholesterol (+0.13 mmol/l). The blood sugar level did not change. There was an insignificant drop of LDL-cholesterol. Hepatic serum enzymes did not change during this treatment. The most marked changes (a drop of LDL-cholesterol by 0.49 mmol/l and rise of HDL-cholesterol by 0.29 mmol/l) were recorded in the group with the highest risk, i.e. group 2. The total drop of triacylglycerols was striking. The body weight and dietary habits did not change during the mentioned 8-month period. The authors consider hormonal replacement therapy indicated. They emphasize its favourable effect on the lipid spectrum of women which is one of the mechanisms of cardiovascular oestrogen protection.
作者关注绝经后女性激素替代治疗期间血脂谱和血糖水平的变化。观察对象为70名女性（平均年龄50岁，36名子宫切除术后女性，绝经平均持续时间4.5 - 5.0年）。在治疗前（雌激素和孕激素联合用药）清晨空腹时采集静脉血，采用酶法评估血脂谱和血糖水平，用药约8个月后再次评估。根据欧洲动脉粥样硬化学会的建议，就治疗前的总胆固醇和高密度脂蛋白胆固醇水平而言，这些女性被分为四组：高胆固醇血症组（5.2 - 7.8 mmol/L）47名女性；高密度脂蛋白胆固醇降低的高胆固醇血症组（低于1.1 mmol/L）5名女性；极高胆固醇组（超过7.8 mmol/L）仅1名女性；血脂谱正常组（总胆固醇低于5.2 mmol/L）17名女性。作者记录到全组总胆固醇显著下降（-0.30 mmol/L）、极低密度脂蛋白胆固醇显著下降（-0.08 mmol/L）和甘油三酯显著下降（-0.27 mmol/L），高密度脂蛋白胆固醇显著升高（+0.13 mmol/L）。血糖水平未发生变化。低密度脂蛋白胆固醇有不显著下降。治疗期间肝血清酶未发生变化。风险最高的组即第2组变化最为显著（低密度脂蛋白胆固醇下降0.49 mmol/L，高密度脂蛋白胆固醇升高0.29 mmol/L）。甘油三酯的总体下降很显著。在上述8个月期间，体重和饮食习惯未发生变化。作者认为激素替代疗法是有必要的。他们强调其对女性血脂谱的有利影响，这是雌激素心血管保护机制之一。
